From Morningstar: 2025-05-08 04:54:00

Novo Nordisk reported 18% constant currency sales growth in Q1 and lowered 2025 sales guidance to 17%. Market watches GLP-1 growth amid competition. Q1 growth fell below expectations, Wegovy sales impacted. Novo plans to counter with improved access. Fair value estimate of $89 maintained, expect stronger growth in second half. Oral GLP-1 medications for obesity seen as next innovation wave. Novo’s launch likely in 2026. Lilly’s rival drug could be cheaper but has limited long-term safety data. No shares held by authors.



Read more at Morningstar: Novo Nordisk Earnings: Compounders Pressured Q1…